Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes

Virology Journal

Volumn 4, Issue , 2007, Pages

  Bonaldo, Myrna C ^a   Mello, Samanta M ^a   Trindade, Gisela F ^a   Rangel, Aymara A ^b   Duarte, Adriana S ^a   Oliveira, Prisciliana J ^a   Freire, Marcos S ^b   Kubelka, Claire F ^a   Galler, Ricardo ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; NEUTRALIZING ANTIBODY; SPACER DNA; GLYCOPROTEIN E, FLAVIVIRUS; RECOMBINANT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

AMINO ACID SEQUENCE; ARTICLE; CELL DIVISION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS; GENE SEQUENCE; IMMUNOPRECIPITATION; METHODOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VERO CELL; VIRUS RECOMBINANT; VIRUS STRAIN; YELLOW FEVER FLAVIVIRUS; ANIMAL; CERCOPITHECUS; CHIMERA; CONFOCAL MICROSCOPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM;

ARTHROPODA; FLAVIVIRUS; YELLOW FEVER VIRUS; YELLOW FEVER VIRUS (STRAIN 17D);

ANIMALS; CERCOPITHECUS AETHIOPS; CHIMERA; FLAVIVIRUS; GENETIC ENGINEERING; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; MICROSCOPY, CONFOCAL; VACCINES, SYNTHETIC; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 37849051431     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-115     Document Type: Article

References (45)

1. Yellow fever vaccine. TP Monath, Vaccines Philadelphia, W.B. Saunders, Plotkin SAOWA, Fourth edition 2004 1095 1176
2. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. MD Co M Terajima J Cruz FA Ennis AL Rothman, Virology 2002 293 151 163 10.1006/viro.2001.1255 11853408
3. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. T Querec S Bennouna S Alkan Y Laouar K Gorden R Flavell S Akira R Ahmed B Pulendran, J Exp Med 2006 203 413 424 10.1084/jem.20051720 16461338
4. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. D Tao G Barba-Spaeth U Rai V Nussenzweig CM Rice RS Nussenzweig, J Exp Med 2005 201 201 209 10.1084/jem.20041526 15657290
5. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. RG van der Most LE Harrington V Giuggio PL Mahar R Ahmed, Virology 2002 296 117 124 10.1006/viro.2002.1432 12036323
6. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. MC Bonaldo RC Garratt PS Caufour MS Freire MM Rodrigues RS Nussenzweig R Galler, J Mol Biol 2002 315 873 885 10.1006/jmbi.2001.5258 11812154
7. New developments in flavivirus vaccines with special attention to yellow fever. KV Pugachev F Guirakhoo TP Monath, Curr Opin Infect Dis 2005 18 387 394 10.1097/01.qco.0000178823.28585.ad 16148524
8. Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface. MC Bonaldo RC Garratt RS Marchevsky ES Coutinho AV Jabor LF Almeida AM Yamamura AS Duarte PJ Oliveira JO Lizeu LA Camacho MS Freire R Galler, J Virol 2005 79 8602 8613 15956601 10.1128/JVI.79.13.8602-8613. 2005
9. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. CJ Lai TP Monath, Adv Virus Res 2003 61 469 509 14714441
10. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. A McAllister AE Arbetman S Mandl C Pena-Rossi R Andino, J Virol 2000 74 9197 9205 10982366 10.1128/JVI.74.19.9197-9205.2000
11. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. G Barba-Spaeth RS Longman ML Albert CM Rice, J Exp Med 2005 202 1179 1184 10.1084/jem.20051352 16260489
12. Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3' noncoding region. JP Mutebi RC Rijnbrand H Wang KD Ryman E Wang LD Fulop R Titball AD Barrett, J Virol 2004 78 9652 9665 15331698 10.1128/JVI.78.18.9652-9665.2004
13. Recombinant bicistronic flaviviruses and methods of use thereof. R Andino A McCallister, US, 2002
14. An infectious West Nile virus that expresses a GFP reporter gene. TC Pierson MS Diamond AA Ahmed LE Valentine CW Davis MA Samuel SL Hanna BA Puffer RW Doms, Virology 2005 334 28 40 10.1016/j.virol.2005.01.021 15749120
15. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. TJ Harvey WJ Liu XJ Wang R Linedale M Jacobs A Davidson TT Le I Anraku A Suhrbier PY Shi AA Khromykh, J Virol 2004 78 531 538 14671135 10.1128/JVI.78.1.531-538.2004
16. Semliki forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity. LL Tannis A Gauthier C Evelegh R Parsons D Nyholt A Khromykh JL Bramson, Vaccine 2005 23 4189 4194 10.1016/j.vaccine.2005.04.005 16005737
17. Kunjin RNA replication and applications of Kunjin replicons. EG Westaway JM Mackenzie AA Khromykh, Adv Virus Res 2003 59 99 140 14696328
18. Construction and applications of yellow fever virus replicons. CT Jones CG Patkar RJ Kuhn, Virology 2005 331 247 259 10.1016/j.virol.2004.10.034 15629769
19. Production and characterization of vaccines based on flaviviruses defective in replication. PW Mason AV Shustov I Frolov, Virology 2006 351 432 443 10.1016/j.virol.2006.04.003 16712897
20. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. SL Allison K Stiasny K Stadler CW Mandl FX Heinz, J Virol 1999 73 5605 5612 10364309
21. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. FA Rey FX Heinz C Mandl C Kunz SC Harrison, Nature 1995 375 291 298 10.1038/375291a0 7753193
22. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. W Zhang PR Chipman J Corver PR Johnson Y Zhang S Mukhopadhyay TS Baker JH Strauss MG Rossmann RJ Kuhn, Nat Struct Biol 2003 10 907 912 10.1038/nsb990 14528291
23. A structural perspective of the flavivirus life cycle. S Mukhopadhyay RJ Kuhn MG Rossmann, Nat Rev Microbiol 2005 3 13 22 10.1038/nrmicro1067 15608696
24. Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope. A Op De Beeck R Molenkamp M Caron A Ben Younes P Bredenbeek J Dubuisson, J Virol 2003 77 813 820 12502797 10.1128/JVI.77.2.813- 820.2003
25. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. L Cocquerel C Wychowski F Minner F Penin J Dubuisson, J Virol 2000 74 3623 3633 10729138 10.1128/JVI.74.8.3623-3633.2000
26. Topogenesis of membrane proteins at the endoplasmic reticulum. M Higy T Junne M Spiess, Biochemistry 2004 43 12716 12722 10.1021/bi048368m 15461443
27. Broadening the horizons for yellow fever: new uses for an old vaccine. HL Van Epps, J Exp Med 2005 201 165 168 10.1084/jem.20042565 15657285
28. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. F Guirakhoo S Kitchener D Morrison R Forrat K McCarthy R Nichols S Yoksan X Duan TH Ermak N Kanesa-Thasan P Bedford J Lang MJ Quentin-Millet TP Monath, Hum Vaccin 2006 2 60 67 17012873
29. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. TJ Chambers RC Weir A Grakoui DW McCourt JF Bazan RJ Fletterick CM Rice, Proc Natl Acad Sci U S A 1990 87 8898 8902 2147282 10.1073/pnas.87.22.8898
30. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. H Nielsen J Engelbrecht S Brunak G von Heijne, Protein Eng 1997 10 1 6 10.1093/protein/10.1.1 9051728
31. Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. M Lobigs E Lee, J Virol 2004 78 178 186 14671099 10.1128/JVI.78.1.178-186.2004
32. Phenotypic analysis of yellow fever virus derived from complementary DNA. RS Marchevsky J Mariano VS Ferreira E Almeida MJ Cerqueira R Carvalho JW Pissurno AP da Rosa MC Simoes CN Santos, Am J Trop Med Hyg 1995 52 75 80 7856829
33. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. PW Chu EG Westaway, Virology 1985 140 68 79 10.1016/0042-6822(85)90446-5 2578239
34. Glycosylation and secretion of yellow fever virus nonstructural protein NS1. PR Post R Carvalho R Galler, Virus Res 1991 18 291 302 10.1016/0168- 1702(91)90025-Q 1828321
35. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. IC Lorenz J Kartenbeck A Mezzacasa SL Allison FX Heinz A Helenius, J Virol 2003 77 4370 4382 12634393 10.1128/JVI.77.7.4370-4382.2003
36. The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals. A Op De Beeck Y Rouille M Caron S Duvet J Dubuisson, J Virol 2004 78 12591 12602 15507646 10.1128/JVI.78.22. 12591-12602.2004
37. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. JM Mackenzie EG Westaway, J Virol 2001 75 10787 10799 11602720 10.1128/JVI.75.22.10787-10799.2001
38. Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress. CY Yu YW Hsu CL Liao YL Lin, J Virol 2006 80 11868 11880 16987981 10.1128/JVI.00879-06
39. Host-cell interaction of attenuated and wild-type strains of yellow fever virus can be differentiated at early stages of hepatocyte infection. A Lefeuvre H Contamin T Decelle C Fournier J Lang V Deubel P Marianneau, Microbes Infect 2006 8 1530 1538 10.1016/j.micinf.2006.01.013 16697681
40. WHO Expert Committee on Biological Standardization. Forty-sixth Report. WHO, World Health Organ Tech Rep Ser 1998 872 i vii, 1-90 9615608
41. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. PJ Bredenbeek R Molenkamp WJ Spaan V Deubel P Marianneau MS Salvato D Moshkoff J Zapata I Tikhonov J Patterson R Carrion A Ticer K Brasky IS Lukashevich, Virology 2006 345 299 304 16412488 10.1016/j.virol.2005.12.001
42. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. CM Rice A Grakoui R Galler TJ Chambers, New Biol 1989 1 285 296 2487295
43. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. PS Caufour MC Motta AM Yamamura S Vazquez Ferreira AV Jabor MC Bonaldo MS Freire R Galler, Virus Res 2001 79 1 14 10.1016/S0168-1702(01)00273-8 11551641
44. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. R Galler KV Pugachev CL Santos SW Ocran AV Jabor SG Rodrigues RS Marchevsky MS Freire LF Almeida AC Cruz AM Yamamura IM Rocco ES da Rosa LT Souza PF Vasconcelos F Guirakhoo TP Monath, Virology 2001 290 309 319 10.1006/viro.2001.1168 11883195
45. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. RS Marchevsky MS Freire ES Coutinho R Galler, Virology 2003 316 55 63 10.1016/S0042-6822(03)00583-X 14599790